Search form

 

Press Releases


Axcan Pharma to present at JP Morgan's Healthcare Conference


Jan 04, 2006 - 11:59 ET

MONT SAINT-HILAIRE, QC, Jan. 4 -

Attention Business/Financial Editors:

TSX SYMBOL (Toronto Stock Exchange): AXP
NASDAQ SYMBOL (NASDAQ National Market): AXCA

Axcan Pharma Inc. ("Axcan"or the "Company") today announced that on Monday, January 9, 2006,
president and chief executive officer, Frank A.G.M. Verwiel, M.D., will present an
overview of the Company at JP Morgan's Healthcare Conference held in San
Francisco, CA. This presentation will take place at 2:30 P.M. local time
(5:30 P.M. EST).

An audio/slide webcast of Axcan's presentation can also be accessed via
the Company's website at www.axcan.com.

Axcan is a leading specialty pharmaceutical company involved in the field
of gastroenterology. The Company markets a broad line of prescription products
sold for the treatment of symptoms in a number of gastrointestinal diseases
and disorders such as inflammatory bowel disease, irritable bowel syndrome,
cholestatic liver diseases and complications related to cystic fibrosis.
Axcan's products are marketed by its own sales force in North America and
Europe. Its common shares are listed on the Toronto Stock Exchange under the
symbol "AXP" and on the NASDAQ National Market under the symbol "AXCA".

"Safe Harbor" statement under the Private Securities Litigation Reform Act of 1995.

This release contains forward-looking statements, which reflect the
Company's current expectations regarding future events. To the extent any
statements made in this release contain information that is not historical,
these statements are essentially forward looking and are often identified by
words such as "anticipate," "expect," "estimate," "intend," "project," "plan"
and "believe." Forward-looking statements are subject to risks and
uncertainties, including the difficulty of predicting FDA and other regulatory
approvals, acceptance and demand for new pharmaceutical products, the impact
of competitive products and pricing, new product development and launch,
reliance on key strategic alliances, availability of raw materials, the
regulatory environment, fluctuations in operating results, the protection of
our intellectual property and other risks detailed from time to time in the
Company's filings with the Securities and Exchange Commission and the Canadian
securities regulatory authorities.



For further information: Isabelle Adjahi, Director, Investor Relations,
Axcan Pharma Inc., (450) 467-2600 ext. 2000, www.axcan.com